Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Cipla-Limited"

49 News Found

Cipla EU to form JV in USA
News | January 07, 2024

Cipla EU to form JV in USA


Cipla to further invest Rs. 42 crore in GoApptiv
Digitisation | December 17, 2023

Cipla to further invest Rs. 42 crore in GoApptiv

Expands patient reach to remotest towns by furthering investment in GoApptiv


Cipla partners with TEACH to create career opportunities for hearing-impaired youth
News | December 01, 2023

Cipla partners with TEACH to create career opportunities for hearing-impaired youth

The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals


Cipla launches drone delivery of critical medicines in Himachal Pradesh
Supply Chain | September 27, 2023

Cipla launches drone delivery of critical medicines in Himachal Pradesh

Commenced operations in flood-affected Himachal Pradesh


Cipla Medpro South Africa to acquire Actor Pharma
News | September 05, 2023

Cipla Medpro South Africa to acquire Actor Pharma

This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities in the South African market


Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr
News | July 27, 2023

Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr

Cipla has reported total income of Rs. 6465.18 crores during the period ended June 30, 2023


Cipla bags sustainable companies rankings for 2022-23
News | July 05, 2023

Cipla bags sustainable companies rankings for 2022-23

Cipla has a robust governance model focused on sustainability


Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
News | May 13, 2023

Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr

Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023


Cipla signs agreement with Novartis for diabetes therapy Galvus range
News | April 11, 2023

Cipla signs agreement with Novartis for diabetes therapy Galvus range

Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore


Cipla launches Cippoint
News | January 18, 2023

Cipla launches Cippoint

Point-of-Care solution to facilitate clinicians in quick and effective decision making